ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
- Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize
- Manufacturing capacity more than triples, with initial capacity to support over 17,000 users
- Volume manufacturing drives gross margin expansion
Utrecht, the Netherlands — May 28, 2026
ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced that commercial‑scale production of Kaleido consumables, including infusion sets and insulin cartridges, has begun at Phillips Medisize, a Molex company and leading global medical technology contract development and manufacturing organization (CDMO). The collaboration more than triples Kaleido consumables production capacity, with initial scale to support over 17,000 users. This expanded supply positions ViCentra to add thousands of new users across Germany, the Netherlands and France through the second half of 2026, with Germany representing the world’s second‑largest insulin pump market.
